The early pioneers of Microbiology, Pasteur, Koch and Ehrlich made many references to antibiosis. 1, 2 Alongside these observations were descriptions of laboratory methodologies, which support the concept of antibiosis. These methodologies included the use of test tubes containing broth, loss of motility and animal protection studies. In the late nineteenth century, other workers also noted in vitro antibiosis well before the discovery of antibiotics. In 1874 William Roberts observed that liquid medium in which the mould Penicillium glaucum was growing, could not easily be contaminated with bacteria. 3 Two years later, John Tyndall made a similar observation that broth supported the growth of either bacteria or moulds, but rarely both.
It was Fleming who reported the inhibitory effect of what eventually became known as penicillin on solid media by observing an area of growth inhibition of staphylococcal colonies adjacent to a Penicillium contaminant on an agar plate. This, however, was not the first description of what was eventually termed agar diffusion as this was first utilized by Beijerinck in 1889 for studying the effect of different auxins on bacterial growth. 4 In addition to the discovery of penicillin, Fleming made two further significant contributions to the field of AST in the 1920s. In 1924 he introduced the use of the ditch plate technique for evaluating antimicrobial qualities of antiseptic solutions. 5 Reddish modified this technique when he cut wells into the agar and filled the wells with antiseptic solutions. 6 The principle of this technique was developed further by the cylinder plate synonymous with the 'Oxford cup', 'fish spine' or 'Heatley cup'. 7 Fleming's second contribution to modern AST was the development of a broth dilution technique using turbidity as an end point determination. 8 This has been described as a forerunner of contemporary minimum inhibitory concentration (MIC) methodology. 2 Fleming later developed the broth dilution method by using pH as an indicator instead of turbidity. 9 Diffusion methods of AST were developed further in the 1940s. In 1940, Heatley introduced the use of absorbent paper for carrying antimicrobial solutions. 10 Filter paper discs incorporating penicillin were utilized by Vincent and Vincent 11 for assaying this newly discovered compound. Mohs introduced a "radial streak disc method " with 15 mm diameter discs. 12 This was the first description of the comparison of a test organism with a sensitive control on the same plate. This method has been described as the forerunner of the Stokes' technique, which until recently was still used in many laboratories in the UK. 2 More paper disc diffusion methods were described in the mid 1940s [13] [14] [15] [16] and Hoyt and Levine 17 described a technique that utilized tablets incorporating penicillin instead of impregnated filter paper. 17 The one-quarter inch (6-6.5 mm) filter paper discs that are still commonly utilized today were first described by Bondi and co-workers in 1947. 18 The 1940s also saw the development of methods incorporating antimicrobial agents into agar; these subsequently became known as agar dilution techniques. As described earlier, Fleming had already diluted antimicrobial agents in liquid medium, 8 but Schmith and Reymann were the first to describe an agar dilution AST method. 19 They determined MICs of sulphapyridine for gonococci. Frisk then described incorporation of penicillin into agar when testing the susceptibility of Streptococcus pneumoniae. 20 Frank and co-workers utilized agar dilution for a study of numerous antibiotic-organism combinations.
21 It was also reported at that time that when agar diffusion and agar dilution techniques were performed correctly, similar results were obtained. 22 It was soon recognized, however, that performing agar dilution MIC estimations for routine bacterial isolates was too time consuming and cumbersome. The procedure was simplified by the introduction of multiple replication devices [23] [24] and by replacing serial dilutions with one or more critical concentrations that separated organisms into resistant and susceptible categories. [25] [26] This method is now commonly referred to as the "breakpoint" technique, a term first used by Ericsson and Sherris. 27 The widespread use of breakpoint techniques was also facilitated by the availability of convenient sources of antimicrobial agents in known quantities, firstly in filter paper strips, 28 then in filter paper pads 29 and finally presented as tablets or in glass vials where the agents have been freeze dried. 30 At an early stage it became apparent to workers using diffusion or dilution techniques that there were many variables affecting AST methods. Early comprehensive studies assessing these variables were reported by many groups. [31] [32] [33] [34] [35] By the end of the 1950s it was apparent that there was a need to standardize AST. Several organizations and investigators began addressing this critical issue. The World Health Organization (WHO) published a report on AST methodology. 36 In 1966, significant progress in standardization of the disc method occurred when Bauer, Kirby and co-workers published their attempt to establish the disc diffusion technique as a practical method of testing with broad application to clinical laboratories. 37 In 1975 this method became the basis of the National Committee for Clinical Laboratory Standards (NCCLS) disc diffusion standards. 38 The results of a WHO sponsored, 10 year International Collaborative Study (ICS) of AST were reported in 1971. 27 The ICS disc diffusion method was largely based on that originally described by Ericsson and colleagues. [39] [40] Many others have followed these initial attempts at standardize AST methodology. Within Europe, at least six different systems for AST are used, 41 those of the Swedish Reference Group for Antibiotics, 42 the Deutsches Institut für Normung (in Germany), 43 the Werkgroep Richtlijnen Gevoeligheidsbepalingen (in the Netherlands), 44 the British Society for Antimicrobial Chemotherapy, 45 the Société Française de Microbiologie 46 and the NCCLS standards (in some countries). 38 All the methods discussed so far have significant limitations. Although several authors have described methods that speed up the results obtained using disc diffusion techniques, [47] [48] the methods currently used still rely mainly on 18-24 hours incubation. Also, most of the methods described do not lend themselves to automated integration into the electronic data processing systems now found in many modern clinical microbiology departments. Furthermore, the clinical and economic pressures for rapid methods with low labour input has resulted in the development of alternative AST methods. 49 One of the first automated AST was the Autobac disc elution system, marketed by Pfizer Diagnostics and introduced in 1974. 50 This machine enabled some results to be reported within 4-6 h of inoculation. Another early automated system, introduced in 1977, was the Abbott MS-2 System, 51 which took 4 h and included organism identification. It was also a disc elution system and generated calculated MIC values. In the same year, the McDonnell Douglas Corporation introduced the AMS System. 52 This was the forerunner of what is known today as the Vitek System. This system utilized dehydrated reagents in sealed plastic cards and contained separate cards for AST and organism identification. It was also in 1977 that standardized microtitre trays containing antimicrobial agents were introduced. This innovation ultimately led to the development of such automated systems as MicroMedia Systems, Sensititre, BBL Sceptor and a whole line of products by Microscan, which started as a basic microtitre system then developed into more complex systems such as the TouchScan, the AutoScan and the MicroScan Walkaway System. 2 All the susceptibility techniques described so far rely on phenotypically testing the bacteria isolated. Although these phenotypic susceptibility testing techniques are relatively simple, they require bacterial isolation, and hence the result is often not available until 2 days after treatment has started. Bergeron & Ouellette 53 highlighted other shortcomings of the phenotypic approach of susceptibility testing, such as the tests being highly dependent on experimental conditions and the fact that more than one method needs to be performed to obtain an accurate susceptibility profile. They also highlighted the fact that different bacterial species have different susceptibilities to the same antibiotic, and that there is no international agreement on breakpoints for interpretation of antimicrobial susceptibility tests.
To increase the speed and reliability of resistance testing, the use of a genotypic approach has been advocated recently, 53 and numerous DNA -based assays have been developed for detection of bacterial resistance genes. [54] [55] [56] Although this approach has been described as a true revolution, it does require a good understanding of resistance mechanisms and the genes involved. 53 Bergeron & Ouellette also highlight other limitations to this approach, as clinical studies will be required to validate the genotypic approach to testing for resistance, the presence of a resistance gene may not always be indicative of resistant bacteria, and conversely, if a gene coding for resistance to an antibiotic is not detected, it may not mean that the bacteria are susceptible to that particular agent. One approach comparing the results of genotypic testing with the results obtained using conventional phenotypic testing of >500 strains of antibiotic-resistant staphylococci, showed that there was an excellent correlation between the resistance genotype and phenotype for methicillin and erythromycin.
As we move into a new millennium, most AST methodologies in operation within routine diagnostic clinical microbiology laboratories will be based on techniques first described at the beginning of the twentieth century. If the limitations of these methods are understood and the procedures standardized, the results generated should offer a reliable guide to susceptibility in a cost effective manner. The newer, genotypic resistance testing methods need to be practical for routine use and competitively priced before they can be considered for routine testing. They also need to identify the organism carrying the resistance gene to avoid reporting on commensals or insignificant organisms in a mixed population. However, they may reduce the risk of increasing bacterial resistance by permitting the withholding of antibiotics from patients who will not benefit from them. It is argued that this will be achieved due to the more rapid identification of bacteria and consequent use of targeted antibiotics, and the fact that broad-spectrum antibiotics will be needed only when dealing with resistant organisms. 53 Obviously, for this to become a reality the new methods will have to yield very rapid results for treatment to be delayed in the case of serious infection. 
